Menu Search
Equities

Dr. Lal PathLabs Ltd

LALPATHLAB:NSI

Dr. Lal PathLabs Ltd

Actions
Health CareMedical Equipment and Services
  • Price (INR)3,057.00
  • Today's Change31.95 / 1.06%
  • Shares traded47.11k
  • 1 Year change+13.63%
  • Beta0.7483
Data delayed at least 15 minutes, as of Nov 22 2024 09:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 20-Nov-24
Select bar for recommendation details.
Recommendations20-Nov-24
Buy1
Outperform7
Hold5
Sell4
Strong Sell3

Share price forecast in INR

The 22 analysts offering 12 month price targets for Dr. Lal PathLabs Ltd have a median target of 3,280.00, with a high estimate of 3,770.00 and a low estimate of 2,400.00. The median estimate represents a 8.43% increase from the last price of 3,025.05.
High24.6%3,770.00
Med8.4%3,280.00
Low-20.7%2,400.00

Dividends in INR

In 2024, Dr. Lal PathLabs Ltd reported a dividend of 24.00 INR, which represents a 100.00% increase over last year. The 14 analysts covering the company expect dividends of 21.51 INR for the upcoming fiscal year, a decrease of 10.38%.
Div growth (TTM)100.00%
More ▼

Earnings history & estimates in INR

On Oct 23, 2024, Dr. Lal PathLabs Ltd reported 2nd quarter 2025 earnings of 15.48 per share. This result was in line with the consensus of the 5 analysts following the company and exceeded last year's 2nd quarter results by 17.99%.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate+6.37%
Dr. Lal PathLabs Ltd reported annual 2024 earnings of 42.98 per share on May 10, 2024.
Average growth rate+16.35%
More ▼

Revenue history & estimates in INR

Dr. Lal PathLabs Limited had 2nd quarter 2025 revenues of 6.60bn. This missed the 6.72bn consensus estimate of the 10 analysts following the company. This was 22.03% above the prior year's 2nd quarter results.
Average growth rate+2.72%
Dr. Lal PathLabs Limited had revenues for the full year 2024 of 22.27bn. This was 10.40% above the prior year's results.
Average growth rate+14.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.